<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784446</url>
  </required_header>
  <id_info>
    <org_study_id>AIO KRK 0205</org_study_id>
    <secondary_id>ML20344</secondary_id>
    <nct_id>NCT00784446</nct_id>
  </id_info>
  <brief_title>First-line Therapy of Stage IV Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Study of Capecitabine/Oxaliplatin (XELOX) in Combination With Bevacizumab and Imatinib as First-line Treatment of Patients With Stage IV Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of safety and toxicity, definition of the dose limiting toxicity (DLT) of the
      combination therapy consisting of Capecitabine, Oxaliplatin, Bevacizumab and Imatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The monoclonal anti-VEGF antibody bevacizumab has been approved for the treatment of stage IV
      colorectal cancer. The tyrosine kinase inhibitor imatinib mesylate has been shown to
      efficiently target PDGF-signalling. Blocking PDGFR-signalling leads to disruption of
      pericytes from the endothelium and reverses the maturation status thereby enhancing the
      sensitivity to anti-VEGF therapy.This background forms a rationale for a combined therapeutic
      PDGF and VEGF inhibition. Since bevacizumab shows best activity when used in combination with
      chemotherapy, capecitabine and oxaliplatin are included in this protocol. Patients with stage
      IV colorectal cancer and no prior chemotherapy can enter the study. Patients receive oral
      imatinib once a day on days 1-21. Oral Capecitabine is given on days 1-14 bid, Oxaliplatin
      and Bevacizumab are given on day 1. Courses are repeated every 22 days in the absence of
      disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of overall response rate and progression free survival.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Stage IV Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX, Bevacizumab, Imatinib</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Capecitabine, Bevacizumab, Imatinib</intervention_name>
    <description>Dose level I:
Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg
Repeat on day 22.
Dose level II:
Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg
Repeat on day 22.</description>
    <arm_group_label>XELOX, Bevacizumab, Imatinib</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Avastin</other_name>
    <other_name>Imatinib</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven inoperable colorectal cancer

          -  Adult patients &gt;= 18 years of age

          -  ECOG &lt;2

        Exclusion Criteria:

          -  Preceding chemo- or immunotherapy with the exception of adjuvant or neoadjuvant
             treatment of non-metastatic disease ending ≥ 6 month prior to study inclusion.
             Progression within 6 month after the end of adjuvant therapy must be excluded.

          -  Other malignancies with the exception of basal cell carcinoma or successfully treated
             carcinoma in situ of the cervix uteri.

          -  No history of severe comorbidities, i. e. uncontrolled hypertension, GI-bleeding,
             congestive heart-failure NYHA class II-IV, symptomatic coronary heart disease,
             myocardial infarction within 1 year prior to study inclusion, serious cardiac
             arrhythmias requiring medication, Grade II or greater peripheral vascular disease and
             other severe uncontrolled co-morbidities

          -  No history of stroke or other CNS-diseases (tumors, seizure, transient ischemic attack
             etc.)

          -  ≥ Grade II peripheral artery vascular occlusive disease

          -  Preexisting neuropathy ≥ Grade 1

          -  Interstitial pneumonia or lung fibrosis

          -  Serious, nonhealing wound, ulcer, or bone fracture

          -  Preceding irradiation an indicator lesion except for documented progressive disease
             during irradiation and termination of irradiation ≥ 4 weeks from study inclusion

          -  Thromboembolic or bleeding events within the last 6 month

          -  Need for therapeutic anticoagulation (heparin, cumarin)

          -  Use of ASS &gt; 325 mg/die or NSAR

          -  Proteinuria &gt; 1+ (stix) as long as urine protein &gt;1g/24h
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Hacker, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Clinic for Haematology and Oncology</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina Krankenhaus</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>January 4, 2013</last_update_submitted>
  <last_update_submitted_qc>January 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Ulrich Hacker</investigator_full_name>
    <investigator_title>PD Dr.</investigator_title>
  </responsible_party>
  <keyword>AIO</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>0205</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Imatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

